정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 450 | Completed | Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia | COVID 19 Pneumonia, Impaired Respiratory Function | Drug: DFV890 Drug: Standard of Care (SoC) |
Phase 2 | Novartis Pharmaceuticals | INDUSTRY | 143 | All | 18 Years ~ 80 Years | Novartis Investigative Site, Caba, Buenos Aires, Argentina Novartis Investigative Site, Buenos Aires, Argentina Novartis Investigative Site, Porto Alegre, RS, Brazil Novartis Investigative Site, Sao Paulo, SP, Brazil Novartis Investigative Site, Hvidovre, Denmark Novartis Investigative Site, Regensburg, Bavaria, Germany Novartis Investigative Site, Hannover, Germany Novartis Investigative Site, Wuerzburg, Germany Novartis Investigative Site, Budapest, Hungary Novartis Investigative Site, Coimbatore, Tamil Nadu, India Novartis Investigative Site, Kolkata, West Bengal, India Novartis Investigative Site, New Delhi, India Novartis Investigative Site, New Delhi, India Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico Novartis Investigative Site, Harderwijk, Netherlands Novartis Investigative Site, San Martin de Porres, Lima, Peru Novartis Investigative Site, San Miguel, Lima, Peru Novartis Investigative Site, Barnaul, Russian Federation Novartis Investigative Site, Chelyabinsk, Russian Federation Novartis Investigative Site, Ekaterinburg, Russian Federation Novartis Investigative Site, Krasnoyarsk, Russian Federation Novartis Investigative Site, Moscow, Russian Federation Novartis Investigative Site, Ryazan, Russian Federation Novartis Investigative Site, Saint Petersburg, Russian Federation Novartis Investigative Site, St Petersburg, Russian Federation Novartis Investigative Site, George, Western Cape, South Africa Novartis Investigative Site, Barcelona, Catalunya, Spain Novartis Investigative Site, Madrid, Spain |
| 449 | Completed | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | COVID-19 Pneumonia, Impaired Respiratory Function | Drug: MAS825 Drug: Matching placebo |
Phase 2 | Novartis Pharmaceuticals | INDUSTRY | 140 | All | 18 Years | Novartis Investigative Site, Chula Vista, California, United States Novartis Investigative Site, Glendale, California, United States Novartis Investigative Site, Irvine, California, United States Novartis Investigative Site, La Mesa, California, United States Novartis Investigative Site, Santa Monica, California, United States Novartis Investigative Site, Torrance, California, United States Novartis Investigative Site, Denver, Colorado, United States Novartis Investigative Site, Washington, District of Columbia, United States Novartis Investigative Site, Idaho Falls, Idaho, United States Novartis Investigative Site, Alexandria, Louisiana, United States Novartis Investigative Site, Baton Rouge, Louisiana, United States Novartis Investigative Site, Lafayette, Louisiana, United States Novartis Investigative Site, Boston, Massachusetts, United States Novartis Investigative Site, Boston, Massachusetts, United States Novartis Investigative Site, Brooklyn, New York, United States Novartis Investigative Site, Asheville, North Carolina, United States Novartis Investigative Site, Columbus, Ohio, United States Novartis Investigative Site, Bend, Oregon, United States Novartis Investigative Site, Philadelphia, Pennsylvania, United States Novartis Investigative Site, Houston, Texas, United States Novartis Investigative Site, Mesquite, Texas, United States |
| 448 | Active, not recruiting | Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19 | COVID-19 | Drug: Favipiravir Drug: Standard of care (SOC) Drug: standard concomitant therapy |
Phase 3 | R-Pharm | INDUSTRY | 168 | All | 18 Years ~ 60 Years | Medical center LLC "Neuroprofi", Korolev, Russian Federation Federal budgetary institution of science "Central Research Institute of Epidemiology" of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare, Moscow, Russian Federation Medical centers JSC "Medsi Group of Companies", Moscow, Russian Federation State budgetary institution of health care of the city of Moscow "City Clinical Hospital №57 of the Moscow City Healthcare Department", Moscow, Russian Federation State budgetary institution of health care of the city of Moscow "City Clinical Hospital №67 n.a. LA Vorokhobova of the Moscow City Healthcare Department", Moscow, Russian Federation State budgetary institution of health care of the city of Moscow "Infectious Diseases Clinical Hospital №1 of the Moscow City Healthcare Department", Moscow, Russian Federation Medical center LLC "Medical Center Eco-safety", Saint Petersburg, Russian Federation St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District", Saint Petersburg, Russian Federation Budgetary healthcare institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1", Voronezh, Russian Federation State Budgetary Healthcare Institution of the Moscow Region "Zhukovskaya City Clinical Hospital"., Zhukovskiy, Russian Federation |
| 447 | Active, not recruiting | Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 | SARS-CoV-2 | Drug: Ensifentrine Dose 1 Drug: Placebo pMDI |
Phase 2 | Verona Pharma Inc | INDUSTRY | 45 | All | 18 Years ~ 80 Years | The University of Alabama at Birmingham, Birmingham, Alabama, United States |
| 446 | Recruiting | Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 | Covid19 | Biological: F-652 Biological: Placebo |
Phase 2 | Generon (Shanghai) Corporation Ltd. | INDUSTRY | 38 | All | 18 Years | Tulane University School of Medicine, New Orleans, Louisiana, United States |
| 445 | Completed | Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 | COVID-19 | Drug: Favipiravir Drug: Standard of care |
Phase 3 | Promomed, LLC | OTHER | 200 | All | 18 Years ~ 80 Years | State Clinical Hospital №50, Moscow, Russian Federation Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation Medical institute Ogarev Mordovia State university, Saransk, Russian Federation Smolensk clinical hospital №1, Smolensk, Russian Federation |
| 444 | Active, not recruiting | Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia | COVID-19 | Drug: FT516 | Phase 1 | Masonic Cancer Center, University of Minnesota | OTHER | 5 | All | 18 Years ~ 76 Years | University of Minnesota, Minneapolis, Minnesota, United States |
